TABLE 2.
In vitro susceptibility patterns of the 25 isolates from the 24 patients with infections caused by VIM-type-producing Gram-negative bacilli treated with ceftazidime-avibactam plus aztreonam
| Patient | Bacterial species | Encoded carbapenemase(s) | MIC (mg/L) ofa: |
Synergy test result | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRO | CAZ | FEP | ATM | IPM | MEM | ETP | CZA | AMK | GEN | CIP | TGC | SXT | ||||
| 1 | C. braakii | VIM type + KPC type | ≥64 | ≥64 | ≥64 | ≥256 | 3 | ≥32 | 4 | ≥256 | 4 | 4 | ≥4 | ≤0.5 | ≤1 | Synergy |
| 2 | C. braakii | VIM type | ≥64 | ≥64 | 2 | 0.19 | 1.5 | 2 | 0.25 | ≥256 | ≤2 | ≤1 | ≥4 | 2 | ≥16 | ND |
| 3 | C. braakii | VIM type | ≥64 | ≥64 | 4 | 12 | ≥32 | 3 | 8 | ≥256 | ≤2 | ≤1 | ≥4 | ≤0.5 | ≥16 | Synergy |
| 4 | C. freundii | OXA-48 type + VIM type | ≥64 | ≥64 | 2 | 0.125 | 12 | ≥32 | 6 | ≥256 | ≤2 | ≥16 | ≥4 | ≤0.5 | ≤1 | Indifference |
| 5 | E. cloacae | VIM type | ≥64 | ≥64 | ≥64 | 0.75 | 1 | 6 | 0.75 | ≥256 | ≤2 | 8 | ≤0.25 | 1 | ≥16 | Synergy |
| 6 | E. cloacae | VIM type | ≥64 | ≥64 | ≥64 | 0.38 | ≥32 | ≥32 | ≥32 | ≥256 | ≤2 | 4 | 2 | 2 | ≥16 | Synergy |
| 7 | E. cloacae | VIM type | ≥64 | ≥64 | 2 | 0.25 | 4 | 0.75 | 0.75 | ≥256 | ≤2 | ≤1 | 0.5 | 1 | ≥16 | Synergy |
| 8 | E. cloacae | VIM type | ≥64 | ≥64 | ≥64 | ≥256 | 3 | 1 | 1.5 | ≥256 | ≤2 | 8 | ≥4 | 2 | ≥16 | Synergy |
| 9 | E. cloacae | VIM type | ≥64 | ≥64 | ≥64 | ≥256 | ≥16 | ≥32 | ≥8 | ≥256 | 4 | 8 | ≥4 | 2 | ≥16 | Synergy |
| 10 | E. cloacae | VIM type | ≥64 | ≥64 | 2 | 0.5 | 8 | 3 | 2 | ≥256 | ≤2 | ≤1 | 1 | 1 | ≥16 | Synergy |
| 11.1 | E. cloacae | VIM type | ≥64 | ≥64 | 4 | 0.75 | 8 | 3 | ≥32 | ≥256 | ≤2 | ≤1 | ≥4 | 2 | ≥16 | ND |
| 11.2 | K. oxytoca | VIM type | ≥64 | ≥64 | 2 | 0.38 | 2 | 0.75 | 0.047 | ≥256 | ≤2 | ≤1 | 2 | 1 | ≥16 | Synergy |
| 12 | E. cloacae | VIM type | ≥64 | ≥64 | ≥64 | 0.19 | 16 | ≥32 | 16 | ≥256 | ≤2 | 8 | 1 | 2 | ≥16 | Synergy |
| 13 | E. cloacae | VIM type | ≥64 | ≥64 | 2 | 0.38 | ≥32 | ≥32 | 8 | ≥256 | ≤2 | ≤1 | 1 | 1 | ≥16 | Synergy |
| 14 | E. cloacae | VIM type | ≥64 | ≥64 | 2 | 1 | 16 | 1.5 | 0.25 | ≥256 | ≤2 | ≤1 | 1 | 2 | ≤1 | Synergy |
| 15 | E. cloacae | VIM type | ≥64 | ≥64 | 16 | 1 | 2 | 1.5 | 1 | ≥256 | ≤2 | 2 | ≥4 | 2 | ≥16 | Synergy |
| 16 | E. coli | VIM type | ≥64 | ≥64 | 2 | 0.064 | 1.5 | 0.38 | 0.38 | ≥256 | ≤2 | ≥16 | ≥4 | ≤0.5 | ≥16 | Indifference |
| 17 | E. coli | VIM type | ≥64 | 64 | 2 | ≥256 | 2 | 0.75 | 0.047 | 64 | ≤2 | 2 | 2 | ≤0.5 | ≥16 | ND |
| 18 | K. oxytoca | VIM type | ≥64 | ≥64 | 2 | 0.125 | 1 | 0.094 | 0.5 | ≥256 | ≤2 | ≤1 | ≤0.25 | ≤0.5 | ≤1 | ND |
| 19 | K. oxytoca | VIM type | ≥64 | ≥64 | 2 | 0.016 | 16 | 1 | 0.19 | ≥256 | ≤2 | 8 | ≤0.25 | 2 | ≥16 | ND |
| 20 | K. oxytoca | VIM type | ≥64 | ≥64 | 2 | 0.016 | 16 | 2 | 1 | ≥256 | ≤2 | 8 | ≤0.25 | 1 | ≥16 | Indifference |
| 21 | K. oxytoca | VIM type | ≥64 | 32 | 2 | 0.19 | 0.75 | 0.064 | 0.047 | 32 | 4 | 8 | ≥4 | 1 | ≥16 | Synergy |
| 22 | K. pneumoniae | VIM type | ≥64 | ≥64 | 24 | 0.75 | 3 | 16 | 4 | 32 | 8 | ≤1 | 2 | 4 | ≤1 | Synergy |
| 23 | P. aeruginosa | VIM type | NA | ≥64 | ≥32 | 4 | ≥16 | ≥16 | NA | ≥256 | 4 | ≥16 | ≥4 | NA | NA | ND |
| 24 | P. aeruginosa | VIM type | NA | ≥64 | ≥32 | 12 | ≥16 | ≥16 | NA | ≥256 | ≥64 | ≥16 | ≥4 | NA | NA | Synergy |
| Total susceptibility (%) | 0 | 0 | 0 | 75 | 33 | 49 | 36 | 0 | 96 | 50 | 17 | 27 | 23 | |||
a
Numbers in boldface represent the resistant isolates according to the current EUCAST clinical breakpoint values. AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; CRO, cefotaxime; CZA, ceftazidime-avibactam; ETP, ertapenem; FEP, cefepime; GEN, gentamicin; IPM, imipenem; MEM, meropenem; NA, not applicable; ND, not done; TGC, tigecycline; SXT, trimethoprim-sulfamethoxazole.